The Cumulative Nature of Pyruvate's Dual Mechanism for Myocardial Protection

Juan A. Crestanello, Joseph Kamelgard, Glenn Whitman

Research output: Contribution to journalArticle

Abstract

Pyruvate (PYR) supplementation protects myocardium from ischemia reperfusion injury. This study was designed to characterize and quantify the mechanism underlying this protection: specifically whether this ability resides in PYR's metabolic effect or in its antioxidant effect. Isolated perfused rat hearts (n = 6/group) were subjected to 15 min of equilibration (EQ), 25 min of ischemia, and 10 min of reperfusion (RP). Glucose was the sole metabolic substrate (Control) or was supplemented with PYR (5 mM) during (a) EQ only (PYREQ group), (b) RP only (PYRRP group), or (c) EQ and RP (PYREQ-RP group). Left ventricular developed pressure (DP) and ±dP/dt were recorded throughout the experiment. ATP concentrations and intracellular pH were determined by 31P NMR spectroscopy. Myocardial creatine kinase (CK) activity was assayed at end EQ and end RP. In vitro, purified CK was assayed and, after exposure to H2O2 (200 μM) and increasing concentrations of PYR (0-6 mM) for 10 min, reassayed to determine the antioxidant effect of PYR. In all cases PYR improved recovery of mechanical function at end RP (DP: Control, 11 ± 1%; PYRRP, 23 ± 6%; PYREQ, 34 ± 8%; PYREQ&RP, 53 ± 7%; P <0.05 between all groups and Control). Ischemic contracture was delayed in hearts that received PYR during EQ (PYREQ and PYREQ&RP: 17.8 ± 0.2 vs 12.5 ± 0.3 min, P <0.001). PYR during EQ (PYREQ and PYREQ&RP) led to higher end ischemic ATP levels (32 ± 4% vs 14 ± 3%, P <0.001) and a more acidic end ischemic pH (5.92 ± 0.02 vs 5.98 ± 0.03 in Control and PYRRP, P <0.05). PYREQ&RP showed the highest end reperfusion ATP levels (55 ± 7% vs 38 ± 4 %, P <0.05 vs other groups). PYR during reperfusion (PYREQ&RP and PYRRP) showed more end reperfusion CK activity (501 ± 9 IU/gV vs 446 ± 13 IU/gV, P <0.001). In vitro, CK exposure to H2O2 abolished 65 ± 6% of its activity, while in the presence of PYR 6 mM abolished only 9 ± 2% (P <0.001). We conclude that PYR given during EQ stimulates anaerobic glycolysis during ischemia as seen by the lower pH and higher end ischemic ATP with a correlative delay in onset of contracture and improvement in DP at end RP. PYR during RP protects CK from hydrogen peroxide-induced inactivation and improves recovery of function. PYR given during EQ and RP has a cumulative effect leading to an even greater recovery of function. PYR must be present both prior to ischemia and during reperfusion for best utilization of its metabolic and antioxidant effects.

Original languageEnglish (US)
Pages (from-to)198-204
Number of pages7
JournalJournal of Surgical Research
Volume59
Issue number1
DOIs
StatePublished - Jul 1995
Externally publishedYes

Fingerprint

Reperfusion
Pyruvic Acid
Creatine Kinase
Recovery of Function
Adenosine Triphosphate
Ischemia
Antioxidants
Ischemic Contracture
Pressure
MB Form Creatine Kinase
Contracture
Glycolysis
Ventricular Pressure
Reperfusion Injury
Hydrogen Peroxide
Myocardium

ASJC Scopus subject areas

  • Surgery

Cite this

The Cumulative Nature of Pyruvate's Dual Mechanism for Myocardial Protection. / Crestanello, Juan A.; Kamelgard, Joseph; Whitman, Glenn.

In: Journal of Surgical Research, Vol. 59, No. 1, 07.1995, p. 198-204.

Research output: Contribution to journalArticle

Crestanello, Juan A. ; Kamelgard, Joseph ; Whitman, Glenn. / The Cumulative Nature of Pyruvate's Dual Mechanism for Myocardial Protection. In: Journal of Surgical Research. 1995 ; Vol. 59, No. 1. pp. 198-204.
@article{80e7afe623dc4ee7a3a7a6504e9ba39a,
title = "The Cumulative Nature of Pyruvate's Dual Mechanism for Myocardial Protection",
abstract = "Pyruvate (PYR) supplementation protects myocardium from ischemia reperfusion injury. This study was designed to characterize and quantify the mechanism underlying this protection: specifically whether this ability resides in PYR's metabolic effect or in its antioxidant effect. Isolated perfused rat hearts (n = 6/group) were subjected to 15 min of equilibration (EQ), 25 min of ischemia, and 10 min of reperfusion (RP). Glucose was the sole metabolic substrate (Control) or was supplemented with PYR (5 mM) during (a) EQ only (PYREQ group), (b) RP only (PYRRP group), or (c) EQ and RP (PYREQ-RP group). Left ventricular developed pressure (DP) and ±dP/dt were recorded throughout the experiment. ATP concentrations and intracellular pH were determined by 31P NMR spectroscopy. Myocardial creatine kinase (CK) activity was assayed at end EQ and end RP. In vitro, purified CK was assayed and, after exposure to H2O2 (200 μM) and increasing concentrations of PYR (0-6 mM) for 10 min, reassayed to determine the antioxidant effect of PYR. In all cases PYR improved recovery of mechanical function at end RP (DP: Control, 11 ± 1{\%}; PYRRP, 23 ± 6{\%}; PYREQ, 34 ± 8{\%}; PYREQ&RP, 53 ± 7{\%}; P <0.05 between all groups and Control). Ischemic contracture was delayed in hearts that received PYR during EQ (PYREQ and PYREQ&RP: 17.8 ± 0.2 vs 12.5 ± 0.3 min, P <0.001). PYR during EQ (PYREQ and PYREQ&RP) led to higher end ischemic ATP levels (32 ± 4{\%} vs 14 ± 3{\%}, P <0.001) and a more acidic end ischemic pH (5.92 ± 0.02 vs 5.98 ± 0.03 in Control and PYRRP, P <0.05). PYREQ&RP showed the highest end reperfusion ATP levels (55 ± 7{\%} vs 38 ± 4 {\%}, P <0.05 vs other groups). PYR during reperfusion (PYREQ&RP and PYRRP) showed more end reperfusion CK activity (501 ± 9 IU/gV vs 446 ± 13 IU/gV, P <0.001). In vitro, CK exposure to H2O2 abolished 65 ± 6{\%} of its activity, while in the presence of PYR 6 mM abolished only 9 ± 2{\%} (P <0.001). We conclude that PYR given during EQ stimulates anaerobic glycolysis during ischemia as seen by the lower pH and higher end ischemic ATP with a correlative delay in onset of contracture and improvement in DP at end RP. PYR during RP protects CK from hydrogen peroxide-induced inactivation and improves recovery of function. PYR given during EQ and RP has a cumulative effect leading to an even greater recovery of function. PYR must be present both prior to ischemia and during reperfusion for best utilization of its metabolic and antioxidant effects.",
author = "Crestanello, {Juan A.} and Joseph Kamelgard and Glenn Whitman",
year = "1995",
month = "7",
doi = "10.1006/jsre.1995.1154",
language = "English (US)",
volume = "59",
pages = "198--204",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The Cumulative Nature of Pyruvate's Dual Mechanism for Myocardial Protection

AU - Crestanello, Juan A.

AU - Kamelgard, Joseph

AU - Whitman, Glenn

PY - 1995/7

Y1 - 1995/7

N2 - Pyruvate (PYR) supplementation protects myocardium from ischemia reperfusion injury. This study was designed to characterize and quantify the mechanism underlying this protection: specifically whether this ability resides in PYR's metabolic effect or in its antioxidant effect. Isolated perfused rat hearts (n = 6/group) were subjected to 15 min of equilibration (EQ), 25 min of ischemia, and 10 min of reperfusion (RP). Glucose was the sole metabolic substrate (Control) or was supplemented with PYR (5 mM) during (a) EQ only (PYREQ group), (b) RP only (PYRRP group), or (c) EQ and RP (PYREQ-RP group). Left ventricular developed pressure (DP) and ±dP/dt were recorded throughout the experiment. ATP concentrations and intracellular pH were determined by 31P NMR spectroscopy. Myocardial creatine kinase (CK) activity was assayed at end EQ and end RP. In vitro, purified CK was assayed and, after exposure to H2O2 (200 μM) and increasing concentrations of PYR (0-6 mM) for 10 min, reassayed to determine the antioxidant effect of PYR. In all cases PYR improved recovery of mechanical function at end RP (DP: Control, 11 ± 1%; PYRRP, 23 ± 6%; PYREQ, 34 ± 8%; PYREQ&RP, 53 ± 7%; P <0.05 between all groups and Control). Ischemic contracture was delayed in hearts that received PYR during EQ (PYREQ and PYREQ&RP: 17.8 ± 0.2 vs 12.5 ± 0.3 min, P <0.001). PYR during EQ (PYREQ and PYREQ&RP) led to higher end ischemic ATP levels (32 ± 4% vs 14 ± 3%, P <0.001) and a more acidic end ischemic pH (5.92 ± 0.02 vs 5.98 ± 0.03 in Control and PYRRP, P <0.05). PYREQ&RP showed the highest end reperfusion ATP levels (55 ± 7% vs 38 ± 4 %, P <0.05 vs other groups). PYR during reperfusion (PYREQ&RP and PYRRP) showed more end reperfusion CK activity (501 ± 9 IU/gV vs 446 ± 13 IU/gV, P <0.001). In vitro, CK exposure to H2O2 abolished 65 ± 6% of its activity, while in the presence of PYR 6 mM abolished only 9 ± 2% (P <0.001). We conclude that PYR given during EQ stimulates anaerobic glycolysis during ischemia as seen by the lower pH and higher end ischemic ATP with a correlative delay in onset of contracture and improvement in DP at end RP. PYR during RP protects CK from hydrogen peroxide-induced inactivation and improves recovery of function. PYR given during EQ and RP has a cumulative effect leading to an even greater recovery of function. PYR must be present both prior to ischemia and during reperfusion for best utilization of its metabolic and antioxidant effects.

AB - Pyruvate (PYR) supplementation protects myocardium from ischemia reperfusion injury. This study was designed to characterize and quantify the mechanism underlying this protection: specifically whether this ability resides in PYR's metabolic effect or in its antioxidant effect. Isolated perfused rat hearts (n = 6/group) were subjected to 15 min of equilibration (EQ), 25 min of ischemia, and 10 min of reperfusion (RP). Glucose was the sole metabolic substrate (Control) or was supplemented with PYR (5 mM) during (a) EQ only (PYREQ group), (b) RP only (PYRRP group), or (c) EQ and RP (PYREQ-RP group). Left ventricular developed pressure (DP) and ±dP/dt were recorded throughout the experiment. ATP concentrations and intracellular pH were determined by 31P NMR spectroscopy. Myocardial creatine kinase (CK) activity was assayed at end EQ and end RP. In vitro, purified CK was assayed and, after exposure to H2O2 (200 μM) and increasing concentrations of PYR (0-6 mM) for 10 min, reassayed to determine the antioxidant effect of PYR. In all cases PYR improved recovery of mechanical function at end RP (DP: Control, 11 ± 1%; PYRRP, 23 ± 6%; PYREQ, 34 ± 8%; PYREQ&RP, 53 ± 7%; P <0.05 between all groups and Control). Ischemic contracture was delayed in hearts that received PYR during EQ (PYREQ and PYREQ&RP: 17.8 ± 0.2 vs 12.5 ± 0.3 min, P <0.001). PYR during EQ (PYREQ and PYREQ&RP) led to higher end ischemic ATP levels (32 ± 4% vs 14 ± 3%, P <0.001) and a more acidic end ischemic pH (5.92 ± 0.02 vs 5.98 ± 0.03 in Control and PYRRP, P <0.05). PYREQ&RP showed the highest end reperfusion ATP levels (55 ± 7% vs 38 ± 4 %, P <0.05 vs other groups). PYR during reperfusion (PYREQ&RP and PYRRP) showed more end reperfusion CK activity (501 ± 9 IU/gV vs 446 ± 13 IU/gV, P <0.001). In vitro, CK exposure to H2O2 abolished 65 ± 6% of its activity, while in the presence of PYR 6 mM abolished only 9 ± 2% (P <0.001). We conclude that PYR given during EQ stimulates anaerobic glycolysis during ischemia as seen by the lower pH and higher end ischemic ATP with a correlative delay in onset of contracture and improvement in DP at end RP. PYR during RP protects CK from hydrogen peroxide-induced inactivation and improves recovery of function. PYR given during EQ and RP has a cumulative effect leading to an even greater recovery of function. PYR must be present both prior to ischemia and during reperfusion for best utilization of its metabolic and antioxidant effects.

UR - http://www.scopus.com/inward/record.url?scp=0029132962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029132962&partnerID=8YFLogxK

U2 - 10.1006/jsre.1995.1154

DO - 10.1006/jsre.1995.1154

M3 - Article

C2 - 7630128

AN - SCOPUS:0029132962

VL - 59

SP - 198

EP - 204

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -